Professor Cheah discusses the ECHO trial, which led to the FDA approval of acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma. This important development addresses a key educational gap in the treatment landscape for MCL.

Vumedi Link: https://www.vumedi.com/video/fda-approval-of-acalabrutinib-br-for-1l-mcl-ph3-echo-trial-subgroup-analysis/.